PolyPid director granted 9,132 stock options
PolyPid Ltd. reported that director Itzhak Krinsky received a grant of stock options for 9,132 Ordinary Shares at an exercise price of $4.4600 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
PolyPid Ltd. reported that director Itzhak Krinsky received a grant of stock options for 9,132 Ordinary Shares at an exercise price of $4.4600 per share. The options vest on a quarterly basis from July 15, 2026 until April 15, 2030 and expire on July 15, 2036.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) F1 | 9,132 | $4.46 | $41K |
Footnotes (1)
- F1. The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030.
Key Figures
Key Terms
Stock option (right to buy) financial
conversion_or_exercise_price financial
vest on a quarterly basis financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock option grant did PolyPid (PYPD) report for director Itzhak Krinsky?
What is the exercise price of the PolyPid (PYPD) stock options granted to Itzhak Krinsky?
How do the PolyPid (PYPD) options granted to Itzhak Krinsky vest over time?
When do the PolyPid (PYPD) stock options granted to Itzhak Krinsky expire?
Was the PolyPid (PYPD) option grant to Itzhak Krinsky reported as a trading plan transaction?
AI-generated analysis. How Rhea-AI works. Not financial advice.